IBBR Fellow Contributes to Research Team That Characterizes the Structure of a Respiratory Syncytial Virus Vaccine Candidate

Printer-friendly versionPrinter-friendly versionPDF versionPDF version
Arrangement of the RSV F fusion protein trimers around the nanoparticle carrier core in the vaccine material, as determined by solution X-ray and neutron scattering.

January 14, 2021 - IBBR Fellow Alexander Grishaev and collaborators at the National Institute of Standards and Technology (NIST) and Novavax characterized the structure of a nanoparticle vaccine candidate for Respiratory Syncytial Virus (RSV), a virus that can cause severe respiratory infections in children. The team applied advanced biophysical measurement methods known as X-ray scattering and neutron scattering to provide insights into the structure and efficacy of the vaccine. This study provided additional information on the structure of the vaccine formulation in solution that can further understanding of activity and facilitate vaccine development.

More information on this study can be found here.